Twenty-six clinical isolates of Mycobacterium abscessus resistant to amikacin were identified. Most isolates were from patients with posttympanostomy tube placement otitis media or patients with cystic fibrosis who had received aminoglycoside therapy. Isolates were highly resistant (MICs ú1024 mg/mL) to amikacin, kanamycin, gentamicin, tobramycin, and neomycin (all 2-deoxystreptamine aminoglycosides) but not to streptomycin. Sequencing of their 16S ribosomal (r) RNA revealed that 16 (94%) of 17 had an AjG mutation at position 1408. In vitro -selected amikacinresistant mutants of M. abscessus and Mycobacterium chelonae had the same resistance phenotype, and 15 mutants all had the same AjG substitution at position 1408. Introducing an rRNA operon from Mycobacterium smegmatis with a mutated AjG at this position into a single functional allelic rRNA mutant of M. smegmatis produced the same aminoglycoside resistance phenotype. These studies demonstrate this 16S rRNA mutation is responsible for amikacin resistance in M. abscessus, which has only one copy of the rRNA operon.
Aminoglycosides have been a major component of therapy
Kanamycin and the closely related amikacin are used for for mycobacterial diseases since the recognition of the remarktreatment of multidrug resistant tuberculosis [13] . Amikacin is able activity of streptomycin against Mycobacterium tuberculoused routinely for treatment of serious infections due to rapidly sis in 1947 [1] . Currently, streptomycin is a second-line agent growing Mycobacterium species, including M. fortuitum and for the treatment of tuberculosis in developed countries and is M. abscessus [14 -15] , while tobramycin is the most active often a first line agent in underdeveloped countries. Streptomyaminoglycoside for M. chelonae isolates [16] . Amikacin has cin is also used for therapy of some slow-growing nontubercualso been used infrequently for the treatment of slow-growing lous Mycobacterium species, including M. kansasii [2] , M. xenontuberculous mycobacterial diseases, including those due to nopi [3] , M. avium complex [4] , M. terrae complex, and M.
M. avium complex [17, 18] , M. kansasii [2] , and Mycobactesimiae [5] . Its resistance among isolates of M. tuberculosis rium haemophilum [19] . The genetic basis of mycobacterial is complex, with high-level resistance associated with point resistance to amikacin, kanamycin, and tobramycin has, until mutations involving the ribosomal protein S12 (rpsL gene) and recently [20, 21] , been unknown. the 16S ribosomal RNA (rRNA) gene (rrs) [6 -11] . The 16S Phenotypic studies have shown that spontaneous mutants rRNA gene region that is mutated involves a pseudoknot strucselected in the laboratory for resistance to amikacin, kanamyture that is believed to be stabilized by the presence of the cin, and tobramycin (2-deoxystreptamine aminoglycosides) are S12 protein [9] . Low-level resistance to streptomycin in M.
not cross-resistant to streptomycin for either M. tuberculosis tuberculosis is yet to be explained on the basis of genetic [22] or the rapidly growing mycobacteria [23] . In addition, alterations [12] but is believed to result from mutations involvrecent studies with Mycobacterium smegmatis have suggested ing cell wall transport [7] .
that the 16S rRNA position 1408 (Escherichia coli numbering system) may be important for resistance to amikacin, tobramycin, and gentamicin [20, 21] . In the present study, we inves-were taken from stock cultures frozen at 070ЊC at the time of random primers, OPA2 (TGCCGAGCTG) and OPA18 (AGGT-GACCGT), which were described by Kauppinen et al. [32] , and susceptibility testing.
In vitro, spontaneous, resistant mutants of clinical isolates of primers INS-2 (GCGTAGGCGTCGGTGACAAA) and IS986-FP (ACGCTCAACGCCAGAGACCA), which were described by M. chelonae and M. abscessus were selected by plating heavy suspensions of organisms on 100 mg/mL amikacin, tobramycin, Linton et al. [33] . The amplification included 40 cycles at 94ЊC for 1 min, 36ЊC for 1 min, and 72ЊC for 2 min. The PCR products and gentamicin and on 1000 mg/mL streptomycin. Single-colony mutants were subcultured, tested for aminoglycoside resistance, were separated by electrophoresis in a 2% agarose gel and detected after ethidium bromide staining. and then stored at 070ЊC. Details of these studies, mutational frequencies, and aminoglycoside MICs were previously published 16S rRNA DNA sequencing. For nucleic acid extraction, a small loopful of bacteria was dispersed in 100 mL H 2 O, heated for in 1985 [23] . Additional isolates were selected at a later date, using Luria-Bertani (LB) medium containing 50 mg/mL amikacin.
10 min at 80ЊC to inactivate the mycobacteria, and then transferred to a 1. The rrnB operon of M. smegmatis was isolated from a genomic library in l ZapII (Stratagene) and identified by nucleic acid secumstances where pretreatment or early treatment amikacin-susceptible and relapse amikacin-resistant isolate was available, quencing. After the phagemid was isolated, the rrnB operon (Ç6 kbp) was excised with SalI and XbaI and cloned into the mycobac-DNA restriction fragment length polymorphism analysis of the 2 isolates was done by use of PFGE [29, 30] and RAPD-PCR [31] .
terial shuttle vector pMV261 [35] , resulting in pMV261 rRNA. PCR mutagenesis of 16S rRNA position 1408. To demonstrate For PFGE, cultures were taken from frozen stocks and subcultured to agar. PFGE was done as previously described for M.
that the AjG transition at position 1408 is responsible for the aminoglycoside-resistant phenotype in M. chelonae and M. ababscessus [29, 30] . In brief, organisms were taken from broth culture and cast into low melting-point agarose plugs and then scessus, PCR techniques were used to mutate 16S rRNA position 1408 (AjG) in the cloned rrnB operon as described previously lysed with 1 mg/mL lysozyme, 1% SDS, and 1 mg/mL proteinase K. Genomic DNA in the agarose plugs was digested by use of the [21] . In addition, the 23S rRNA position 2058 was mutated (AjG) to allow for selection using clarithromycin. Sequence analinfrequent cutting restriction endonucleases DraI and XbaI and then separated by PFGE, using the CHEF Mapper system (Bioysis confirmed that the respective mutations were introduced into the wild-type rRNA operon by this procedure. Rad, Richmond, CA) at 14ЊC for 20 h at 6 V/cm.
RAPD-PCR was done as previously described [31] . In brief, Transformation of the PCR mutant plasmid construct of rrnB into a single allelic rRNA mutant of M. smegmatis. The cloned cell suspensions were treated with lysozyme, proteinase K, and SDS. The lysates were extracted by phenol and chloroform, and rrnB operon plasmid construct containing the mutated 16S rRNA 1408 AjG and 23S rRNA 2058 AjG was transformed into an DNA was precipitated by isopropanol. Fifty microliters of the mixture was used for PCR, which contained 60 mM Tris-HCL rrnB mutant, a genetically engineered M. smegmatis rRNA knockout strain with a single functional rRNA operon [21] derived from (pH 9.0); 2. taken nor available for the other 22 pretreatment or early treatthe method described by Jacobs et al. [37] , with the modification ment case pairs. MICs for streptomycin were generally in that bacteria were grown in brain-heart infusion medium (Oxoid, the 64 -256 mg/mL range for the amikacin-resistant strains London) with 0.05% Tween 80. When an OD of 0.4 at A 600 was (18/21) , values which are comparable to currently observed and achieved, cells were incubated on ice for 1.5 h. The cells then previously published values for wild-type strains [23] . MICs have were collected by centrifugation (10 min, 5000 g, 4ЊC), washed been reported previously for 9 ear isolates [35, 36] , 1 respiratory with an equal volume of ice-cold glycerol (10%), and centrifuged.
isolate (MC194) [23] , and 1 blood isolate (MC92) [23] .
Cells were subsequently resuspended in a one-tenth volume of Susceptibility results for the in vitro mutants of M. chelonae the medium and again centrifuged at 5000 g for 10 min at 4ЊC. The pellet was resuspended in the same volume, and the cells were and M. abscessus are shown in table 3. Their MICs were comagain centrifuged under the same conditions for 15 min. Finally, parable to clinical aminoglycoside-resistant isolates. Suscepticells from 1 L of culture medium were resuspended in 2 mL of bilities to paromomycin (neomycin E) were also determined glycerol (10%). For electroporation, 100 mL of freshly prepared for 8 M. abscessus mutants. The parental strains E-123 and cells was mixed with 1 mg of DNA and put on ice for 5 min.
ATCC 19977 had low MICs (õ50 mg/mL), while the aminoElectroporation was performed in 0.2-cm cuvettes with a single glycoside-resistant mutants had MICs of ú200 mg/mL to paropulse (2.5 kV, 25 mF, 1000 V; Bio-Rad). Cells were immediately momycin. MICs for some of these isolates were reported preresuspended in 1 mL of brain-heart infusion medium and incubated viously [23] . [29] . By RAPD-PCR and the Organisms. Twenty-six clinical isolates of M. abscessus resistant to amikacin (1/patient) were identified. There was no use of three primers, however, each pretreatment susceptible strain and subsequent resistant strain from the same patient known relationship between any of the patients, and all were from different hospitals. The isolates fell into 3 disease groups.
gave identical patterns, supporting that resistance is related to a change in the original susceptible infecting strain. A The first group comprised 14 ear isolates (54% of the strains) from patients with chronic otitis media following tympanos-RAPD-PCR comparison of these strains using primer IS986-FP is shown in figure 1 . tomy tube placement. One of these isolates was from a large outbreak [38] . The second group comprised 8 respiratory iso-16S rRNA sequencing. Seventeen clinical isolates resistant to the 2-deoxystreptamine aminoglycosides underwent rDNA selates (31%) from patients with chronic lung disease. The remaining 4 isolates (15%) were from patients with a variety of quencing, with all but 1 (94%) having a guanine-for-adenine substitution at the 16S rRNA position 1408 (table 2; figure 2). diseases, including endocarditis, catheter sepsis, and chronic wound infection. The majority of patients with pulmonary or Of four pretreatment or early treatment isolates that were susceptible to amikacin and the other 2-deoxystreptamine aminoglycomiscellaneous infections (9/12 or 75%) were suspected or known to have underlying cystic fibrosis.
sides, 3 were sequenced: All had a wild-type position 1408 ( [38] . ‡ Neomycin exposure is presumed since these patients all had history of topical ear drops (with neomycin the usual aminoglycoside present in drops). § Case previously reported [23] .
and mutagenized at the 16S rRNA position 1408 (AjG) and demonstrated that high-level resistant mutants to amikacin (MIC ú1024 mg/mL) could be regularly obtained in M. cheloat 23S rRNA position 2058 (AjG). This construct was then electroporated into M. smegmatis mc 2 155 KO-low, which has nae and M. abscessus (identified at that time collectively as M. chelonei) at a frequency of 10 05 -10
07
. These mutants were a single functional rRNA operon (knockout strain). Twelve transformants were selected from the clarithromycin-concross-resistant to other 2-deoxystreptamine aminoglycosides (gentamicin, tobramycin, and kanamycin) but produced no taining selection media. These isolates were all resistant to amikacin, tobramycin, and gentamicin, with MICs of ú200 change in the MICs for streptomycin. High-level resistant mutants could be selected on any of the other 2-deoxystreptamine mg/mL, and to clarithromycin. As a control, a construct that was PCR mutagenized only at 23S rRNA position 2058 aminoglycosides with a similar frequency and the same crossresistance pattern, demonstrating that all of the drugs were (AjG) was selected on the clarithromycin-containing medium selecting an identical phenotype. and then tested for aminoglycoside resistance. Of 12 transHigh-level streptomycin resistance in M. abscessus (MIC formants, all were clarithromycin resistant but had wild-type ú1024 mg/mL) resulted in no change in the MICs to the aminoglycoside MICs (õ50 mg/mL) to amikacin, tobramycin, 2-deoxystreptamine aminoglycosides. An aminoglycoside aceand gentamicin.
tylating enzyme similar in its profile to aminoglycoside acetyltransferase (3)-III or -IV was evident in almost all (28/29 or Discussion 97%) pre-treatment susceptible isolates [40] , with no change An initial study of aminoglycoside resistance in rapidly in detectable aminoglycoside-modifying enzymes in in vitro mutants or resistant strains recovered from patients on therapy. growing mycobacteria was published in 1985 [23] . This study [38] . ‡ MICs previously reported [23] .
No change in plasmid profiles was evident among resistant The first piece of evidence of the importance of the 16S rRNA position 1408 (E. coli numbering system) in aminoglycoisolates. These findings supported a mutational event to explain the resistance, but genetic techniques to determine this were side susceptibility was based on a study with an aminoglycoside-resistant strain of Streptomyces tenjimariensis that pronot yet available.
Since that study [23] was published ú10 years ago, a great duced the little-known aminoglycoside istamycin. Following cloning of the resistance factor in Streptomyces lividans and deal more has been learned about mycobacterial genetics. M. chelonae and M. abscessus are known to contain a single copy demonstration that it was a methylase, Beauclerk and Cundiffe [44] showed that it methylated the adenine in 16S rRNA posiof the rRNA operon [30] , making phenotypic expression of single point mutations in the ribosome much more likely than in most tion 1408, with resultant high-level resistance to kanamycin and apramycin. bacterial species that contain multiple copies. Mutational resistance to the newer macrolides, clarithromycin and azithromycin, A second and more convincing piece of evidence of the importance of the 16S position 1408 in 2-deoxystreptamine was shown to result from a single point mutation at A-2058 or A-2059 (E. coli numbering system) in the 23S rDNA of M.
aminoglycoside resistance was recently shown with studies with M. smegmatis. Using recombination techniques that allow chelonae and M. abscessus [30] , as well as in other mycobacterial species with single genomic copies of the rRNA operon, such as for ''knockout'' of one of the two functional copies of the rRNA (rrn) operon in M. smegmatis, it was possible to select Mycobacterium intracellulare [41] 
NOTE. WT Å wild type; ND Å not tested. * Mutants selected on amikacin (AM), kanamycin (KM), and streptomycin (SM).
gentamicin-or amikacin-resistant mutants in the knockout sinpMV 261. Transformation of the single rrn allelic mutant of M. smegmatis with this construct with selection on clarithrogle allelic rrn strain at a rate of 10
08
. These single allelic rrn mutants were cross-resistant to other 2-deoxystreptamine mycin produced resistant transformants (12/12) with high-level amikacin resistance. aminoglycosides, and 10 of 10 mutants had the 16S rRNA 1408 AjG mutation [21] . We utilized a cloned rrnB operon The final available evidence involved studies of amikacinand kanamycin-resistant isolates of Mycobacterium bovis and that had been mutagenized at both 16S rRNA position 1408 (AjG) and at the 23S rRNA position 2058 (AjG), the latter M. tuberculosis. Studies of M. bovis bacille Calmette-Guérin, which has a single ribosomal operon, showed that 10 of 10 in being known to confer clarithromycin resistance, and inserted it into the extrachromosomally replicating, multicopy vector vitro -selected mutants had this mutation, as did 8 of 8 clinical binding as it led to the formation of a specific binding pocket. An interaction of equivalent geometry cannot be formed with a G1408 -A1493 configuration, and paromomycin was found to bind only weakly to this mutant structure [49] .
With in vitro -selected aminoglycoside-resistant mutants of M. chelonae, all had amikacin MICs of ú1024 mg/mL when tested by broth microdilution MICs (7 mutants tested), all showed resistance to paromomycin (ú200 mg/mL), and all had the position 1408 AjG mutation. In contrast, some in vitroselected mutants of M. abscessus had amikacin MICs of isolates of amikacin-and kanamycin-resistant M. tuberculosis (which also has a single rRNA operon) [21] . These three pieces 128 -512 mg/mL, and position 1408 AjG mutations were often not detectable (data not shown). When heavy growth on of evidence combined with the current study demonstrate that the substitution of guanine for adenine at position 1408 is all the 2-deoxystreptamine aminoglycosides in agar (200 mg/mL) was used as the basis for mutant selection, all of these the major mechanism of 2-deoxystreptamine aminoglycoside resistance in most mycobacterial species. Because of the small isolates had the 1408 AjG mutation. This suggests that there is a group of M. abscessus isolates that have low-level numbers of pretreatment (4) and resistant (17) clinical strains that were sequenced, we cannot exclude the possibility of ge-2-deoxystreptamine aminoglycoside resistance due to an alteration other than bp 1408. Of interest, all clinically resistant netic sites other than 16S rRNA position 1408 being involved in 2-deoxystreptamine aminoglycoside susceptibility. Additional isolates of M. abscessus had high-level resistance, and all had the 1408 AjG mutation. A similar observation was recently studies may be required to help resolve this possibility.
The sequencing data in the current study and previous studies made with M. avium strains resistant to clarithromycin [43] and with M. tuberculosis strains with low-level resistance to with other mycobacterial species [20] provided several surprises. The first was that a single base pair, position 1408, streptomycin [7] . A previous MIC study of in vitro 2-deoxystreptamine aminoappeared to be responsible for most high-level resistance to amikacin (MIC ú1024 mg/mL) and the other 2-deoxystreptglycoside -resistant mutants of M. chelonae and M. abscessus that included many of the isolates sequenced in the current amine aminoglycosides, including paromomycin. Presuming that the 2-deoxystreptamine aminoglycosides bind the 16S study [23] demonstrated that these mutants showed little or no change in their MICs to streptomycin and that in vitro -serRNA, this binding almost certainly involves multiple bases, but apparently mutation of only one is found in drug-resistant lected, high-level streptomycin-resistant mutants showed no change in MICs for amikacin and the other aminoglycosides. mutants.
Methylase genes conferring resistance at other sites on the The streptomycin MICs in the clinical amikacin-resistant isolates of M. abscessus in the current study were similar to those 16S rRNA have been described (e.g., G-1405, which confers resistance to kanamycin plus gentamicin [44] , has been identiof untreated wild-type strains. The demonstration that highlevel resistance to the 2 aminoglycoside groups is associated fied from a strain of Micromonospora purpurea that produces gentamicin). At least four other sites (E. coli positions 1405, with different mutations (streptomycin with an rpsL or rrs mutation and the 2-deoxystreptamine aminoglycosides at posi-1409, 1491, and 1495) within 16S rRNA have been identified at which mutations in other organisms cause resistance to tion 1408 of the 16S rRNA) is consistent with the prior phenotypic observations. aminoglycosides, such as paromomycin [44] .
The second surprise was that substitution of only one of The current study did not address aminoglycoside resistance in M. fortuitum, which is the other major pathogen among three potential nucleotides was observed (i.e., 1408 AjG) among clinical isolates and in vitro -selected M. abscessus rapidly growing mycobacterial species. The previously published phenotype study [23] demonstrated that amikacin-resismutants with a detectable mutation. With macrolide resistance, which involves A-2058 or A-2059 in the peptidyl transferase tant mutants could be selected in vitro on 10 mg/mL (frequency 
